Famciclovir 250 mg Tablets

Adult dose

1. Treatment of herpes zoster Adults: Administer 250 mg of famciclovir per dose orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of an initial episode of genital herpes Adults: Administer 250 mg of this medicine per dose orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Administer 125 mg of this medicine per dose orally twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this medicine per dose orally twice daily. Temporarily discontinue treatment periodically every 6～12 months to assess any change in the natural course of the disease. 5. Patients with renal impairment: Since the creatinine clearance of this medicine is reduced in patients with renal impairment, dosage adjustment should be undertaken with care. The dosage for these patients is as follows. 1) Treatment of herpes zoster and an initial episode of genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose twice daily 10～29: 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose twice daily 10～29: 125 mg per dose once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose twice daily 10～29: 125 mg per dose twice daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight(kg) × (140-age)}/ {72 × serum creatinine(mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, it is preferable to administer this medicine every 48 hours, taking the dialysis interval into consideration. Hemodialysis for 4 hours reduces the plasma concentration of this medicine by approximately 75%; therefore, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dosage adjustment is required in patients with chronic compensated liver disease. Since there is insufficient treatment experience in patients with overt chronic decompensated liver disease, no definite recommended dose has been established.

This medication should not be administered to certain patients. Patients with allergies to this medication or any of its components, patients with lactose intolerance or genetic lactose-related issues, and patients allergic to soybean oil, soy, or peanuts should not take this medication. Patients with impaired kidney function or abnormalities in fat metabolism, or those at risk for lipid emulsion, should use this medication cautiously. While taking this medication, symptoms such as headache, nausea, dizziness, drowsiness, skin rash, itching, abdominal pain, and diarrhea may occur, and serious side effects such as thrombocytopenia, hallucinations, palpitations, abnormal liver function, and acute renal failure have been reported rarely. This medication does not cure genital herpes, so sexual contact should be avoided when symptoms are present, and safe sex practices should be maintained. Additionally, if symptoms of central nervous system disturbances such as dizziness or drowsiness occur, driving or operating machinery should be avoided. Patients with slightly impaired liver function do not need dose adjustments, but caution is advised for patients with severe liver impairment as efficacy may be reduced. Patients at risk for lipid overload should monitor their blood lipid levels and adjust the dosage of this medication if necessary. This medication does not have significant interactions with other drugs; however, care is needed when used alongside drugs excreted by the kidneys as blood concentrations may increase. Women who are pregnant or breastfeeding should be cautious with this medication, and women of childbearing potential should also exercise special caution. Children under 18 years of age are not recommended for this medication as its safety and effectiveness have not been established. In older adults, dose adjustment is usually not required, but adjustments should be made if kidney function is impaired. In case of overdose, appropriate treatment is necessary, and blood dialysis can be used to reduce drug concentration. Store this medication in a cool, dry place below 30 degrees Celsius, and keep it in a safe location out of the reach of children. It is advised to avoid transferring it to another container as it may affect the quality of the medication.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is best to keep it in a cool, dry place below 30 degrees Celsius.

Appearance

White round film-coated tablets

Package unit

21 tablets/box [7 tablets/PTP X 3]